CA3180143A1 - Procede de production de lymphocytes t autologues genetiquement modifies - Google Patents

Procede de production de lymphocytes t autologues genetiquement modifies

Info

Publication number
CA3180143A1
CA3180143A1 CA3180143A CA3180143A CA3180143A1 CA 3180143 A1 CA3180143 A1 CA 3180143A1 CA 3180143 A CA3180143 A CA 3180143A CA 3180143 A CA3180143 A CA 3180143A CA 3180143 A1 CA3180143 A1 CA 3180143A1
Authority
CA
Canada
Prior art keywords
cells
cell
bioreactor
soluble
rocking
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3180143A
Other languages
English (en)
Inventor
Yijun Liu
Kathryn A. HENCKELS
Carlos ARBELAEZ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CA3180143A1 publication Critical patent/CA3180143A1/fr
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14Blood; Artificial blood
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14Blood; Artificial blood
    • A61K35/18Erythrocytes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14Blood; Artificial blood
    • A61K35/19Platelets; Megacaryocytes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/461Cellular immunotherapy characterised by the cell type used
    • A61K39/4611T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/463Cellular immunotherapy characterised by recombinant expression
    • A61K39/4632T-cell receptors [TCR]; antibody T-cell receptor constructs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/464Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643Vertebrate antigens
    • A61K39/4644Cancer antigens
    • A61K39/464402Receptors, cell surface antigens or cell surface determinants
    • A61K39/464411Immunoglobulin superfamily
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0636T lymphocytes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)

Abstract

La présente invention concerne la production de lymphocytes T autologues génétiquement modifiés destinés à être utilisés dans des applications de thérapie cellulaire.
CA3180143A 2020-04-15 2020-04-15 Procede de production de lymphocytes t autologues genetiquement modifies Pending CA3180143A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2020/028192 WO2021211104A1 (fr) 2020-04-15 2020-04-15 Procédé de production de lymphocytes t autologues génétiquement modifiés

Publications (1)

Publication Number Publication Date
CA3180143A1 true CA3180143A1 (fr) 2021-10-21

Family

ID=70476574

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3180143A Pending CA3180143A1 (fr) 2020-04-15 2020-04-15 Procede de production de lymphocytes t autologues genetiquement modifies

Country Status (6)

Country Link
EP (1) EP4135724A1 (fr)
JP (1) JP2023522642A (fr)
AU (1) AU2020442490A1 (fr)
CA (1) CA3180143A1 (fr)
MX (1) MX2022012990A (fr)
WO (1) WO2021211104A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210324333A1 (en) * 2020-04-15 2021-10-21 Amgen Inc. Method for enhancing production of genetically engineered autologous t cells
CA3205810A1 (fr) 2020-12-22 2022-06-30 Amgen Inc. Recepteurs de lymphocytes t specifiques de mage-b2
AU2022421695A1 (en) 2021-12-21 2024-05-30 Amgen Inc. Dcaf4l2-specific t-cell receptors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6319494B1 (en) 1990-12-14 2001-11-20 Cell Genesys, Inc. Chimeric chains for receptor-associated signal transduction pathways
IL104570A0 (en) 1992-03-18 1993-05-13 Yeda Res & Dev Chimeric genes and cells transformed therewith
US7572631B2 (en) * 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
WO2015120096A2 (fr) * 2014-02-04 2015-08-13 Marc Better Méthodes de production de lymphocytes t autologues utilisés pour traiter les tumeurs malignes à lymphocytes b et d'autres cancers, et compositions associées
GB201509202D0 (en) * 2015-05-28 2015-07-15 Ge Healthcare Bio Sciences Ab Semi-static cell culture
US20210030793A1 (en) * 2017-10-26 2021-02-04 St. Jude Children's Research Hospital, Inc. Methods and compositions for treating cd33+ cancers and improving in vivo persistence of chimeric antigen receptor t cells

Also Published As

Publication number Publication date
WO2021211104A1 (fr) 2021-10-21
MX2022012990A (es) 2023-01-11
JP2023522642A (ja) 2023-05-31
EP4135724A1 (fr) 2023-02-22
AU2020442490A1 (en) 2022-11-17

Similar Documents

Publication Publication Date Title
US20230190814A1 (en) Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy
CN107922925B (zh) 用于自然杀伤细胞扩增的方法
Lamers-Kok et al. Natural killer cells in clinical development as non-engineered, engineered, and combination therapies
KR101881520B1 (ko) Nk 세포의 증식
CN112639083A (zh) 制备表达嵌合抗原受体的细胞的方法
US9670459B2 (en) Production method for cell populations
CN105112370A (zh) 一种体外刺激外周血γδT细胞高效增殖的方法及其应用
CA3180143A1 (fr) Procede de production de lymphocytes t autologues genetiquement modifies
Shimasaki et al. Natural killer cell reprogramming with chimeric immune receptors
WO2011052638A1 (fr) Procédé de production de cellules tueuses induites par la cytokine
US20210324333A1 (en) Method for enhancing production of genetically engineered autologous t cells
Zhou et al. iCaspase 9 suicide gene system
Shimasaki et al. Engineering of natural killer cells for clinical application
US20210324331A1 (en) Process for generating genetically engineered autologous t cells
US20200297768A1 (en) Cd28 t cell cultures, compositions, and methods of using thereof
CN111206052B (zh) 一种滋养细胞、其制备方法及其在大量快速扩增γδT细胞中的应用
GB2484869A (en) Pharmaceutical composition containing transiently surviving CTL
EP3941487B1 (fr) Cultures de cellules t cd28, leurs compositions et leurs méthodes d'utilisation
US20240117309A1 (en) Methods for expanding t cell populations
Class et al. Patent application title: METHOD FOR NATURAL KILLER CELL EXPANSION
Stroncek et al. Production of Clinical T Cell Therapies
Golden et al. Clinical development of natural killer cells expressing chimeric antigen receptors
WO2022241232A1 (fr) Production de lymphocytes t modifiés à partir de cellules souches
AU2022366817A1 (en) Engineering stem cell t cells with multiple t cell receptors

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20231206

EEER Examination request

Effective date: 20231206